Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D

Author:

DeJong Colette1,Kazi Dhruv S.2,Dudley R. Adams1,Chen Randi3,Tseng Chien-Wen34

Affiliation:

1. Center for Healthcare Value, Philip R. Lee Institute for Health Policy Studies, Department of Medicine, University of California, San Francisco School of Medicine, San Francisco

2. Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts

3. Pacific Health Research and Education Institute, Honolulu, Hawaii

4. Department of Family Medicine and Community Health, University of Hawaii John A. Burns School of Medicine, Honolulu

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Reference6 articles.

1. Angiotensin-neprilysin inhibition versus enalapril in heart failure.;McMurray;N Engl J Med,2014

2. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure, a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.;Yancy;Circulation,2016

3. Adoption of sacubitril/valsartan for the management of patients with heart failure.;Sangaralingham;Circ Heart Fail,2018

4. Epidemiology and risk profile of heart failure.;Bui;Nat Rev Cardiol,2011

5. Full coverage for preventive medications after myocardial infarction.;Choudhry;N Engl J Med,2011

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3